Theralase adds omitted Adstiladrin safety, prescribing details in corrected Q2 2026 release

Theralase issued a corrected replacement of its Q2 2026 financial statements, adding omitted safety and prescribing information for Adstiladrin. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theralase Technologies Inc. published the original content used to generate this news brief via (Ref. ID: 202609180700NEWSFILECNPR____20260918_314778_1) on September 18, 2026, and is solely responsible for the information contained therein. (C)